Literature DB >> 14730178

Lactoferrin inhibits growth of malignant tumors of the head and neck.

Jeffrey S Wolf1, Daqing Li, Rodney J Taylor, Bert W O'Malley.   

Abstract

Lactoferrin, a naturally occurring glycoprotein found in breast milk, has previously been shown to have antimicrobial properties and recently has been demonstrated to inhibit malignant tumor growth, presumably through immunomodulation. We hypothesized that intratumoral injection of human and murine recombinant lactoferrin would decrease the growth of malignant tumors in vivo. Using an orthotopic murine model for both squamous cell carcinoma and fibrosarcoma of the floor of the mouth, we administered lactoferrin directly into the tumors using variable dosing strategies. Additionally, we performed in vitro experiments to assess whether the effects of lactoferrin are due to direct cytotoxicity. Our results revealed growth inhibition of 50% (p=0.03)and 54% (p=0.01) as compared with controls for both human and murine tumor cells in immunodeficient and immunocompetent mice, respectively. There was a more dramatic effect in immunocompetent models which may identify immunomodulation as an important mechanism of action for lactoferrin. Support for immunomodulation as a possible mechanism was the lack of any difference between controls and the experimental groups in vitro. Lactoferrin proved effective in reducing malignant tumor growth in a murine model. These properties offer hope for its use as a primary or adjuvant chemotherapeutic agent. Further investigation focused on mechanism and delivery is needed. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14730178     DOI: 10.1159/000075220

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  6 in total

1.  Does lactoferrin behave as an immunohistochemical oncofetal marker in bone and cartilage human neoplasms?

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Giuseppe Speciale; Michele A Rosa; Giovanni Tuccari
Journal:  Pathol Oncol Res       Date:  2010-10-24       Impact factor: 3.201

2.  Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo.

Authors:  Jeffrey S Wolf; Guoyan Li; Atul Varadhachary; Karel Petrak; Mark Schneyer; Daqing Li; Julina Ongkasuwan; Xiaoyu Zhang; Rodney J Taylor; Scott E Strome; Bert W O'Malley
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

3.  Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.

Authors:  Teresa G Hayes; Gerald S Falchook; Atul Varadhachary
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

4.  Lactoferrin Ameliorates Dry Eye Disease Potentially through Enhancement of Short-Chain Fatty Acid Production by Gut Microbiota in Mice.

Authors:  Samuel Connell; Motoko Kawashima; Shigeru Nakamura; Toshihiro Imada; Hiromitsu Yamamoto; Kazuo Tsubota; Shinji Fukuda
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

5.  Milk-Derived Proteins and Peptides in Head and Neck Carcinoma Treatment.

Authors:  Theresa Wang; Xinyi Liu; Yah Ying Ng; Kiera Tarleton; Amy Tran; Thomas Tran; Wen Yue Xue; Paul Youssef; Peiyu Yuan; Daniel Zhang; Rita Paolini; Antonio Celentano
Journal:  Biomolecules       Date:  2022-02-10

6.  Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.

Authors:  Pei Zhang; Jinzhong Liu; Wenlu Li; Shanshan Li; Xinguang Han
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.